Sei Investments Co. Reduces Stock Holdings in Cencora, Inc. $COR

Posted by Brenda Bartman on Jul 24th, 2026

Sei Investments Co. trimmed its holdings in Cencora, Inc. (NYSE:COR – Free Report) by 0.5% during the first quarter, Holdings Channel.com reports. The fund owned 504,571 shares of the company’s stock after selling 2,302 shares during the period. Sei Investments Co.’s holdings in Cencora were worth $158,505,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of COR. Assetmark Inc. increased its position in Cencora by 57.0% in the fourth quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after buying an additional 24,431 shares during the last quarter. ExodusPoint Capital Management LP purchased a new position in shares of Cencora during the 4th quarter valued at $16,487,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Cencora by 162.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 289,370 shares of the company’s stock valued at $97,735,000 after buying an additional 179,086 shares during the last quarter. Impact Partnership Wealth LLC bought a new position in shares of Cencora during the 1st quarter worth $1,170,000. Finally, PFA Pension Forsikringsaktieselskab purchased a new stake in Cencora in the 4th quarter worth about $59,145,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 1.3%

Shares of NYSE COR opened at $304.57 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company has a market cap of $59.26 billion, a P/E ratio of 23.36, a P/E/G ratio of 1.67 and a beta of 0.58. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The business has a 50-day simple moving average of $283.47 and a two-hundred day simple moving average of $316.51.

Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter in the prior year, the company earned $4.42 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora announced that its Board of Directors has initiated a share buyback program on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Insiders Place Their Bets

In other news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Evercore set a $360.00 price objective on Cencora in a research note on Wednesday, April 8th. Citigroup cut their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Barclays reduced their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. William Blair began coverage on shares of Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Finally, UBS Group upped their price target on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $367.75.

Get Our Latest Analysis on Cencora

Cencora Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.